Heparin supplementation of nonionic contrast agents

Area of Science:

• Pharmacology
• Biomaterials Science
• Clinical Medicine

Background:

• Diatrizoate is a long-established contrast agent known for inhibiting clot formation in medical devices.
• Catheter and syringe thrombosis remains a clinical challenge during procedures like angiography.
• Nonionic contrast agents (ioversol, iohexol, iopamidol) and ioxaglate are alternatives to diatrizoate.

Purpose of the Study:

• To quantify the heparin concentration needed to achieve the anticoagulant potency of diatrizoate in nonionic contrast agents.
• To evaluate the anticoagulant potency of ioxaglate relative to diatrizoate.
• To establish heparin dosing guidelines for preventing clot formation with alternative contrast agents.

Main Methods:

• 180 glass syringes were prepared with diatrizoate, ioxaglate, or nonionic contrast agents mixed with varying heparin concentrations.
• Syringes were contaminated with venous blood from 10 healthy volunteers.
• Clot weight was measured after 30 minutes of simulated handling during angiography.

Main Results:

• The average heparin level required for ioversol, iohexol, or iopamidol to match diatrizoate's anticoagulant effect was below 1.5 U (USP)/mL.
• The 97.5 percentile analysis suggested a heparin dose of 3.5 U/mL is likely necessary to ensure adequate anticoagulation for the general population.
• Ioxaglate's anticoagulant potency was also assessed in comparison to diatrizoate.

Conclusions:

• Nonionic contrast agents require significantly lower heparin concentrations than previously assumed to prevent catheter clot formation.
• A heparin dose of 3.5 U/mL is recommended for ioversol, iohexol, or iopamidol to provide a sufficient safety margin during angiographic procedures.
• These findings aid in optimizing anticoagulation protocols to minimize thrombotic complications associated with contrast media use.